DIL Dyadic International

Dyadic International, Inc. (AMEX: DIL), a biotechnology company, announced today that Mark Emalfarb, CEO and Glenn Nedwin, Ph.D., Chief Scientific Officer and President of Dyadic's Biosciences Business, will make the following presentations to the financial community: -- on Tuesday, April 11, 2006 at approximately 1:15 p.m. EDT in Chicago and -- on Tuesday, April 18, 2006 at approximately 7:45 a.m. EDT in New York. Mr. Emalfarb and Dr. Nedwin will review Dyadic's C1 Host Technology development program, the company's cellulosic ethanol opportunity, as well as its progress in industrial enzymes and the advancement of C1 Expression Technology for use in the development and production of antibodies and other therapeutic proteins. Both presentations will be webcast live and can be accessed at http://www.dyadic-group.com. An archive of the webcasts will be available for approximately 30 days. Prior to joining Dyadic in March 2006, Dr. Nedwin was co-founder and President of Novozymes, Inc., a research & development subsidiary of Novozymes A/S, Denmark (Copenhagen Stock Exchange: NZYMb.CO). About Dyadic Dyadic International, Inc. is engaged in the development, manufacture and sale of biological products using a number of proprietary fungal strains to produce enzymes and other biomaterials, principally focused on a system for protein production based on the patented Chrysosporium lucknowense fungus, known as C1. Dyadic currently sells more than 45 liquid and dry enzyme products to more than 200 industrial customers in approximately 50 countries. Dyadic intends to utilize its patented enabling and proprietary platform technologies on its own behalf and under license to business collaborators for the discovery, development and manufacture of biological products from genes to produce targeted protein products for diverse markets. Cautionary Statement for Forward-Looking Statements Certain statements contained in this press release are "forward-looking statements." These forward-looking statements involve risks and uncertainties that could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For a discussion of these risks and uncertainties, please see our filings from time to time with the Securities and Exchange Commission, which are available free of charge on the SEC's web site at http://www.sec.gov, including our Annual Report on Form 10-KSB for the year ended December 31, 2005. Except as required by law, we expressly disclaim any intent or obligation to update any forward-looking statements.